Evidence map›Paper›PMID 40213684›Full record

ArticleFrontiers in pharmacology2025

Agonist efficacy at the β

Clare R Harwood, David A Sykes, Theo Redfern-Nichols, Owen Underwood, Colin Nicholson, Armin N Khoshgrudi, Eline J Koers, Graham Ladds, Stephen J Briddon, Dmitry B Veprintsev

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Using a NanoBRET-Based Ligand-Binding Assay at the βPharmacology research & perspectives · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clare R HarwoodDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
David A SykesDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Theo Redfern-NicholsDepartment of Pharmacology, University of Cambridge, Cambridge, United Kingdom.
Owen UnderwoodZ7 Biotech Ltd., Nottingham, United Kingdom.
Colin NicholsonDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Armin N KhoshgrudiDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Eline J KoersDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Graham LaddsCentre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Nottingham, United Kingdom.
Stephen J BriddonDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Dmitry B VeprintsevDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The β Methods: We used NanoBRET technology to measure ligand-induced binding of purified Venus-mini-G Results: The 12 β Conclusion: The association rate (

Indexed as

association rate kondissociation rate koffefficacyG protein-coupled receptorkineticsβ2-adrenoceptor

Identifiers

PMID40213684
PMCPMC11983327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.